WORK PACKAGE 10
As part of WP10 – Appraisal of orphan medicinal products, HTA appraisal/reimbursement processes for rare disease treatments in most EU and EEA Member States, Canada and New Zealand have been documented.
These country vignettes are now publicly available and can be found in the list below. More information on how this was done can also be found in the background document below.
Click on a flag to download the country vignette [PDF}